{"id":"NCT02301910","sponsor":"Supergene, LLC","briefTitle":"Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI","officialTitle":"Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05-16","primaryCompletion":"2016-12-01","completion":"2016-12-01","firstPosted":"2014-11-26","resultsPosted":"2025-03-20","lastUpdate":"2025-03-20"},"enrollment":382,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myocardial Infarction"],"interventions":[{"type":"DRUG","name":"Recombinant staphylokinase","otherNames":["Fortelyzin"]},{"type":"DRUG","name":"Tenecteplase","otherNames":["Metalyse"]}],"arms":[{"label":"Recombinant staphylokinase","type":"EXPERIMENTAL"},{"label":"Tenecteplase","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the study is to determine if single-bolus recombinant nonimmunogenic staphylokinase is effective and save thrombolytic agent in patients presenting ST-segment elevation myocardial infarction in comparison to tenecteplase.","primaryOutcome":{"measure":"The Number of Participants With Reperfusion","timeFrame":"90 min after fibrinolysis","effectByArm":[{"arm":"Recombinant Staphylokinase","deltaMin":133,"sd":null},{"arm":"Tenecteplase","deltaMin":131,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.87"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":24},"locations":{"siteCount":17,"countries":["Russia"]},"refs":{"pmids":["20598969","10220625","10475182","11530146","12847070","9313600","10936478","17963623","9500599"],"seeAlso":["http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html"]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":191},"commonTop":["hematuria"]}}